Amphastar Pharmaceuticals (AMPH) Gross Profit (2013 - 2026)

Amphastar Pharmaceuticals' Gross Profit history runs 14 years deep, the most recent figure standing at $70.3 million for Q1 2026.

• On a quarterly basis, Gross Profit fell 17.51% year-over-year to $70.3 million in Q1 2026; TTM through Mar 2026 was $341.1 million, a 7.55% decrease from a year earlier, with the FY2025 full-year figure at $356.1 million, down 4.76% from the prior year.
• Gross Profit slipped to $70.3 million in Q1 2026 per AMPH's latest filing, from $85.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $108.4 million in Q3 2023 and bottomed at $55.8 million in Q1 2022.
• The 5-year median for Gross Profit is $85.7 million (2025), against an average of $82.4 million.
• Across the five-year window, Gross Profit surged 85.27% in 2023 and retreated 17.51% in 2026, its largest moves.
• Year by year, Gross Profit stood at $71.2 million in 2022, then soared by 35.09% to $96.1 million in 2023, then decreased by 9.87% to $86.6 million in 2024, then slipped by 1.13% to $85.7 million in 2025, then decreased by 17.92% to $70.3 million in 2026.
• Per Business Quant, the three latest AMPH Gross Profit figures stand at $70.3 million (Q1 2026), $85.7 million (Q4 2025), and $98.6 million (Q3 2025).